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WE have  assessed  the  effect  of  platelet-activating
factor (PAF), a biologically active phospholipid pres-
ent in the human marrow, on the growth of human
marrow  and  blood  CD34+ progenitors.  While  the
metabolization rate of PAF by CD34+ cells is low (weak
acetylhydrolase and acylation processes) it is readily
catabolized by the acetylhydrolase activity present in
the  growth  medium  (10%  fetal  calf  serum  +  10%
5637-conditioned  medium).  Treatment  of  marrow
CD34+ cells with the non-metabolizable PAF agonist
C-PAF (1 nM to 100 nM) immediately before semi-solid
culture significantly (P < 0.01) decreased the number
of BFU-E but not  of CFU-GM colonies.  Treatment  of
marrow or blood CD34+ cells with C-PAF (10–100 nM)
for 3 days in liquid medium before semi-solid culture
significantly (P < 0.01) decreased the number of BFU-
E  and  CFU-GM colonies.  Treatment  of  blood  CD34+
cells with the two PAF receptor antagonists CV 3988
and BN 52021 (1 m M) had no significant effect on the
number of BFU-E and CFU-GM colonies suggesting no
role  of  endogenous  PAF  in  these  processes.  These
results  show  that  exogenous  PAF  downregulates
human erythropoiesis and myelopoiesis, a result that
might be of importance during inflammatory states.
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Introduction
Studies  highlight  the  role  of lipidic compounds on
human  haematopoiesis.1–6 They  demonstrate  that
leukotrienes  and  prostaglandin  E  upregulate  and
downregulate  human  myelopoiesis, respectively. By
contrast  leukotrienes  and  prostaglandin  E  down-
regulate  and  upregulate  human  erythropoiesis,
respectively. Platelet-activating factor (PAF) is a phos-
pholipid molecule produced by inflammatory stimu-
lated cells.7 PAF levels are regulated by an acetylhy-
drolase activity (AHA) which converts PAF into lyso
PAF which is then reacylated into membrane phos-
pholipids  by  an  acyltransferase  activity  (ATA).7
Numerous studies report the immunoregulatory prop-
erties of PAF . Its inhibiting or activating  effects are
shown  in  various  cell  types  such  as  monocytes/
macrophages, polymorphonuclear neutrophils, eosi-
nophils and T - and B-lymphocytes.7–9 Studies report
that  complex  interrelations  exist  between  PAF  and
cytokines. Thus,  PAF  stimulates  the  production  of
several cytokines such as interleukin (IL)-1, IL-6 and
tumour necrosis factor-alpha (TNF-a ) which, in turn,
may enhance PAF synthesis.7–9
While  PAF  is  present  in  the  human  bone  mar-
row,10,11 its  effects  on  the  growth  of  myeloid  and
erythroid  progenitors  is  not  documented.  CD34,  a
surface  antigen  expressed  on  haemopoietic  stem/
progenitor  cells  that  disappears  at  later  stages  of
differentiation  can  be  used  to  select  this  popula-
tion.12,13 In this study we have examined the effect
of  PAF  on  human  haematopoiesis  by  investigating
its effects on the growth of granulocyte-macrophage
(CFU-GM)  and  erythroid  progenitor  cells  (BFU-E)
from  purified  human  marrow  and  blood  CD34+
cells. We also examined PAF metabolism by CD34+
cells.
Materials and Methods
Collection and preparation of mononuclear
cells
Sternum  bone  marrow  cells  were  harvested  by
aspiration into heparinized tubes (Vacutainer system,
Becton  Dickinson,  Meylan,  France)  from  patients
referred  for  diagnosis  according  to  the  Helsinki
recommendations.  Mononuclear  cells  were  isolated
by separation on a Ficoll gradient (400 3 g, 20min)
and washed twice with Hanks’s balanced salts solu-
tion (Gibco, Cergy Pontoise, France). None of these
patients had an haematological malignancy and their
myelograms were normal. Peripheral blood stem cells
were collected from lymphoma patients in complete
remission undergoing apheresis for autologous trans-
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and  CFU-GM  controls  were  harvested  in  freezing
tubes  from  the  final  apheresis  product  just  before
freezing. They  were  then  stored  in  liquid  nitrogen
with apheresis autograft bags until used.
Selection of CD34
+ cells
Mononuclear  bone  marrow  cells  were  used  imme-
diately after Ficoll and washing procedures. Periph-
eral blood stem cells were rapidly defreezed in a 37°C
water bath, then diluted and washed in saline with 4%
human  serum  albumin  (HSA).  CD34+ cells  were
obtained by magnetic cell sorting (MiniMACS, Tebu,
Le Perray en Yvelines, France) as previously descri-
bed.14 The entire procedure was made according to
the  manufacturer’s  instructions.  Briefly,  cells  were
resuspended at a concentration of 1 3 108/0.3ml. The
blocking reagent and the antibody reagent (0.1ml for
1 3 108 cells) were added to the cell suspension and
incubated at 4°C for 15min. Cells were then washed
with 4ml of washing buffer (PBS/0.5% human serum
albumin  (HSA)/5mM  EDTA)  and  centrifuged.  Cells
were recovered in cold washing buffer (0.4ml for 1 3
108 cells)  and  incubated  with  a  suspension  of
submicroscopic magnetic beads (0.1ml for 1 3 108
cells)  for  15min  at  4°C. After  washing,  cells  were
recovered in 0.5ml of cold washing buffer, filtered,
applied to the separation column previously placed in
a magnetic field, and washed with 2ml of buffer. Cells
which did not bind CD34+ antibody passed through
the  column  while  CD34+ cells  were  retained. The
CD34+ cells  were  eluted  by  removing  the  column
from the magnetic field and washing the column with
1ml buffer. After a new step of washing CD34+ cells
were recovered in IMDM and counted.
Flow cytometric analysis of selected CD34
+
cells
Samples  were  analysed  on  a  Profile  Coulter  using
Epics Profile Software to determine the efficiency of
the selection. One-hundred m l of cell suspension was
incubated at room temperature for 30min with 5m l
phycoerythrin  (PE)-labelled  anti-CD34  (HPCA-2)
monoclonal antibody or PE-labelled monoclonal con-
trol (mouse immunoglobulin) and washed twice with
PBS  supplemented  with  2%   HSA.  Fixation  with
paraformaldehyde (PFA 1% ) was performed at the end
of staining. The purified population contained 84 ±
2% of CD34+ cells (mean ± SEM of 17 experiments,
range 72–98%).
Semisolid cultures
Two experimental conditions were used for CD34+
cells.  Firstly,  freshly  isolated  marrow  CD34+ cells
were incubated 30 min at 37°C in 1ml IMDM with
various  concentrations  of  PAF  (Sigma,  St  Quentin-
Fallavier, France) and of the non-metabolizable PAF
agonist  1-O-hexadecyl-2-N-methycarbamyl-sn-glycero-
3-phosphocholine (C-PAF) (Sigma) before methylcel-
lulose  culture.  Secondly,  freshly  isolated  marrow
CD34+ cells  and frozen  blood mononuclear CD34+
cells were grown for 3 days in liquid medium with
various concentrations of PAF , C-PAF , CV 3988 and BN
52021 (two potent PAF receptor antagonists) (Tebu)
or the appropriate vehicle (10m l of 2%  HSA) before
colony formation in methylcellulose cultures. Marrow
or  blood  CD34+ cells  (4  3 103)  were  grown  in
96-round-bottomed  well  microtitre  plates  in  100m l
IMDM with 10% fetal calf serum (FCS) (Gibco), 10%
5637-conditioned medium and antibiotics (100U/ml
penicillin and 100m g/ml streptomycin) at 37°C in 5%
CO2 in air.
Colony  assays  were  performed  in  both  experi-
ments  with  CD34+ cells  (5  3 102)  cultured  in
35mm  Petri  dishes  in  sixplicates  for  14  days  at
37°C  in  5%   CO2 in  air  in  100%  humidity.  The
culture  medium  (1ml/dish)  was  a  mixture  of
IMDM  with  0.8%  methylcellulose,  30%  FCS,  1%
detoxified  bovine  serum  albumin,  10ng/ml  Stem
Cell  Factor  (Tebu),  40ng/ml  interleukin-3  (Sandoz,
Rueil-Malmaison,  France),  3U/ml  erythropoietin
(R&D  systems,  Oxfordshire,  UK),  a -thioglycerol
(0.1mM)  and  10%  5637-conditioned  medium.
CFU-GM and BFU-E  derived colonies were  counted
under  an  inverted  microscope  in  the  same  dish.
The differences of colony number between controls
and  test  dishes  were  analysed  using  Wilcoxon’s
test.
[
3H]PAF metabolism and AHA assay
CD34+ cells (1 3 105) were washed twice with HBSS
and  were  incubated  at  37°C  in  1ml  of  IMDM  for
various periods of time in the presence of [3H]alkyl-
PAF  (final  concentration  0.05nmol/tube;  0.5m Ci)
(Amersham) complexed to HSA (final concentration
2mg/ml). Experiments were performed in duplicate.
The PAF metabolism was assessed after lipid extrac-
tion.15 Recovery  of  added  radioactivity  after  lipid
extraction was 85%. The labelled compounds derived
from [3H]alkyl-PAF were separated using TLC plates
(Silica Gel 60 (20 3 20cm, 0.25mm)) eluted with
chloroform/methanol/acetic  acid/water  (50:25:8:4,
v/v).11 Each lane was divided in areas of 0.5cm length
which were scraped into vials and radioactivity was
measured on a  Packard  liquid scintillation  counter.
PAF , lyso PAF , phosphatidylcholine (PC) and neutral
lipid (NL) were used as standards. AHA was assessed
in culture medium according to the method of Miwa
et  al.16 Results  were  expressed  as  picomoles  PAF
degraded  per  min  per  ml  as  means  of  duplicate
determinations. The variation between duplicates was
less than 5% .
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We first investigated PAF catabolism by human CD34+
cells.  Cells  were  incubated  with  [3H]alkyl  PAF  in
IMDM alone. After 24h of incubation 73%, 18% , 5%
and 4% of the label migrated with PAF , lyso PAF , 1-alkyl
analogue of PC and NL, respectively (mean of three
experiments). When cells were incubated in IMDM +
10% FCS + 10%  5637-conditioned medium (growth
medium), 0% , 90% , 6% and 4% of the label migrated
with PAF ,  lyso PAF , 1-alkyl  analogue of PC and NL,
respectively.  After  1h  of  incubation  in  growth
medium,  100%   of  the  [3H]PAF  was  converted  into
[3H]lyso PAF demonstrating  a high AHA. The  mean
AHA  levels  detected  in IMDM  with  10%   5637-con-
ditioned  medium,  10%   FCS,  and  10%   5637-con-
ditioned medium + 10% FCS were 204 ± 16, 1676 ±
190 and 2160 ± 115pmol/min/ml, respectively (mean
± SEM of three experiments). No significant AHA was
detected in IMDM alone.
We next assessed the effect of PAF and C-PAF on the
growth of human CFU-GM and BFU-E. Due to its rapid
metabolism, no significant effect was found with PAF .
By contrast treatment of marrow CD34+ cells with the
non-metabolized PAF  agonist  C-PAF  (1–100nM)  sig-
nificantly (P < 0.01, seven independent experiments)
decreased the number of BFU-E but not of CFU-GM
colonies (Fig. 1). Treatment of marrow CD34+ cells
with C-PAF (10–100nM) for 3 days in liquid medium
before  semi  solid  cultures,  significantly  (P <  0.01,
three independent experiments) decreased the num-
ber of BFU-E and CFU-GM colonies (Fig. 2A). In similar
experimental  conditions,  C-PAF  significantly  (P <
0.01, three independent experiments) decreased the
growth  of BFU-E and CFU-GM colonies from blood
CD34+ cells (Fig. 2B). In these experimental condi-
tions  the  PAF  receptor  antagonist  CV  3988  (1m M)
slightly  (P <  0.05,  four  independent  experiments)
enhanced  the  growth  of  BFU-E  colonies  compared
with  control  dishes  (23  ±  2  colonies  vs.  19  ±  2
colonies  for  CV  3988-treated  cells  and  controls,
respectively) while BN 52021 (1m M) had no effect
(20 ± 2 colonies). CV 3988 and BN 52021 had no
effect on CFU-GM growth (54 ± 5 colonies and 56 ± 5
colonies vs. 52 ± 5 colonies for CV 3988-treated cells,
BN 52021-treated cells and controls, respectively).
Discussion
Lipidic mediators (such as prostaglandins and leuko-
trienes) affect the growth of human CFU-GM and BFU-
E progenitors.1–6 The rationale for analysing the role
of PAF on the growth of human myeloid and erythroid
progenitors is based on several points. First, PAF is
PAF and human CD34
+ cells
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FIG. 1. Direct effect of C-PAF on the number of BFU-E and
CFU-GM  colonies  derived  from  freshly  isolated  marrow
CD34+ cells.  Percentage  of  variation  of  colony  numbers
compared with control values (seven  independent  experi-
ments).  *P <  0.01  (Wilcoxon’s  test).  Colony  numbers  in
controls were 37 ± 7 and 85 ± 11 for BFU-E and CFU-GM,
respectively.
FIG. 2. Effect of C-PAF on the growth of BFU-E and CFU-GM
colonies from marrow (A) and blood (B) CD34+cells cultured
3 days in liquid medium before colony assay. (A) Percentage
of variation of colony numbers compared with control values
(three independent experiments). *P< 0.01 (Wilcoxon’s test).
Colony numbers in controls were 28 ± 4 and 51 ± 3 for BFU-E
and  CFU-GM,  respectively.  (B)  Percentage  of  variation  of
colony number compared with control values (three inde-
pendent experiments). *P < 0.01 (Wilcoxon’s test). Colony
number in controls were 16 ± 2 and 37 ± 3 for BFU-E and
CFU-GM, respectively.present in the human bone marrow.10,11 Second, PAF
modulates the  growth  of  various human  cell  types
including adherent bone marrow cells.17 Third, PAF
stimulates  the  eosinophilic  and  basophilic  differ-
entiation  from  human  blood  progenitors.18 Finally,
PAF  increases  the  erythroid  colony formation  from
cultured  CD34+ haematopoietic  progenitors  by
enhancing  the  prolactin  synthesis  by  human  bone
marrow stromal cell feeders.19
The use of the  CD34  antigen  is a  useful  way to
obtain haematopoietic stem/progenitor cells.12,13 It is
expressed on 1–3% of adult bone marrow cells,20 and
about 0.1%  of normal blood mononuclear cells.21 As
the population of bone marrow CD34+ progenitors
differ from that in blood by a higher percentage of
more commited progenitors,22 we have investigated
the effect of PAF on both marrow and blood CD34+
cells. Our percentage of CD34+ cells after magnetic
cell  sorting  is  similar  to  recent  studies  using  this
method.14,23 All CD34+ cells are not haematopoietic
progenitors. Thus, cells that give rise to fibroblast-like
stromal  elements  of  the  bone  marrow  may  be
recovered in the CD34+ cell fraction  but  represent
less than 5% of total CD34+ cells.24 Moreover colonies
of  fibroblastic  cells  were  not  documented  in  our
CD34+ cell cultures.
Our studies are done with a non-metabolizable PAF
agonist since  PAF  is readily catabolized by an AHA
present  in  the  culture  medium.  By  contrast  the
metabolization rate of PAF by human CD34+ cells is
low (weak intracellular AHA and ATA). The nanomolar
concentrations  of  C-PAF  active  in  this  study  are
physiologically significant since PAF is detected in the
human marrow at a mean level of about 1nM.11 The
use  of  1nM  of  C-PAF  may  be  compared  with  a
continuous stimulation with this physiologic dose of
PAF . In the present study treatment of marrow CD34+
cells with C-PAF immediately before semi solid culture
decreased the growth of BFU-E but not of CFU-GM
colonies suggesting a direct effect of C-PAF on human
erythroid  progenitor  cells.  An  effect  of  C-PAF  on
marrow or blood CFU-GM colonies was found after 3
days of treatment in liquid medium before semi solid
culture  suggesting  an  indirect  effect  through  an
elevated  production  of  inhibitory  factor(s)  or  a
decreased  production  of  stimulatory  factor(s).  In
vitro studies report that PAF modulates the produc-
tion of several molecules such as IL-1, IL-3, IL-4, IL-6,
TNF-a , prostaglandins and leukotrienes that regulate
human CFU-GM growth.7–9,25 No role of endogenous
PAF  may  be  documented on the growth  of CD34+
cells. Thus, the two PAF receptor antagonists CV 3988
and BN 52021 have no effect on the number of CFU-
GM colonies. In contrast to BN 52021, CV 3988 has a
weak effect on BFU-E colonies. A similar difference
between these two drugs has been found concerning
their ability to inhibit superoxide anion generation in
a human B cell line.26 In this previous study the weak
effect of CV 3988 was attributed to its incorporation
in  cell  membrane  leading  to  a  non-specific  effect.
Such an effect may also be suggested in our study.
Bellone  et  al.19 have  recently  reported  that  PAF
stimulates  the  erythroid  colony  formation  from
CD34+ haematopoietic progenitors by enhancing the
prolactin synthesis by human bone marrow stromal
cells. Our present results indicate that, in absence of
a  marrow  stromal  cell  feeder,  PAF  decreases  the
growth of erythroid and myeloid CD34+ progenitors
highlighting not only the putative role of PAF during
early  steps  of  human  haematopoiesis  but  also  the
complexity  of  the  regulation  of  the  bone  marrow
progenitor growth.
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